Minims (Prednisolone Sodium Phosphate)

Prednisolone Sodium Phosphate, the active ingredient in Minims, is a corticosteroid presented as an ophthalmic solution for ocular use. It is employed to control inflammation in the eye following surgery, allergic reactions, and other inflammatory ocular conditions. It is formulated for topical instillation directly onto the ocular surface, allowing rapid absorption and localized anti‑inflammatory activity.

GNH USA supplies Minims as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides full regulatory documentation to support import and distribution across multiple markets.

Prednisolone Sodium Phosphate is used to treat ocular inflammatory conditions by reducing swelling and immune‑mediated responses.

- Post‑operative ocular inflammation: reduces swelling, pain and redness after eye surgery. - Allergic conjunctivitis: alleviates itching, tearing and conjunctival hyperemia caused by allergens. - Uveitis: controls intra‑ocular inflammation and prevents tissue damage in anterior or intermediate uveitis. - Other inflammatory eye conditions: manages inflammation associated with keratitis, scleritis or ocular trauma.

Topical ocular corticosteroids may cause a range of local and systemic adverse reactions, most of which are dose‑related and reversible upon discontinuation.

Common Side Effects: - Burning or stinging sensation upon instillation. - Transient blurred vision. - Increased intra‑ocular pressure. - Mild ocular irritation or redness. - Temporary tearing.

Serious or Rare Side Effects: - Secondary ocular infection (bacterial, fungal or viral). - Persistent elevation of intra‑ocular pressure leading to glaucoma. - Cataract formation with prolonged use. - Delayed wound healing after ocular surgery. - Systemic adrenal suppression (rare with extensive use).

When prescribing Minims, clinicians should consider several safety measures to minimize risks and ensure optimal therapeutic outcomes.

- Assess intra‑ocular pressure: monitor IOP before treatment and periodically during therapy. - Screen for ocular infections: avoid use in active bacterial, fungal or viral eye infections unless combined with appropriate antimicrobial therapy. - Limit duration: use the lowest effective dose for the shortest period required to control inflammation. - Caution in glaucoma patients: evaluate risk‑benefit as steroids can raise IOP. - Pregnancy and lactation: use only if the potential benefit justifies the potential risk, as safety data are limited. - Store at ambient temperature: keep the bottle below 25 °C, protect from light, and retain in the original container with the cap tightly closed.

Prednisolone Sodium Phosphate may interact with other medications, altering its safety or efficacy profile.

Major Interactions (Avoid): - Systemic CYP3A4 inhibitors: may increase systemic exposure if significant ocular absorption occurs. - Concurrent use of potent ocular NSAIDs: can increase risk of corneal melting.

Moderate Interactions (Monitor Closely): - Other topical corticosteroids: additive IOP‑raising effect; monitor pressure. - Anticholinergic eye drops: may reduce tear film stability, increasing irritation. - Systemic immunosuppressants: may enhance overall immunosuppression; observe for infections.